Understand FDA changes in terms of your exact products.

Product-level FDA monitoring, delivered to your inbox. Which of your products are affected — by name and ingredient — with the analysis and action items already written.

From: Policy Canary <alerts@policycanary.io>

Your Marine Collagen Powder — Action Required

March 4, 2026 · 7:14 AM

Urgent · Action Required

Marine Collagen Powder

The FDA cited three companies for identity-testing failures on marine-sourced collagen in the last 90 days. Your product's ingredient profile matches the cited substances. Lab protocols need updating.

Action Items

  1. Verify identity-testing protocols for marine collagen
  2. Request updated CoA from supplier
  3. Document compliance review for FDA inspection readiness

Deadline

Q2 2026

Source

21 CFR 111.75(a)(1)(ii)

THE DIFFERENCE

Every FDA action.
Matched to your products.

Not summaries — product intelligence. Each card shows what Policy Canary actually delivers to your inbox.

Email Intelligence

Intelligence delivered, not searched for

Every alert arrives in your inbox, scoped to your products — with the analysis and action items already written.

From: Policy Canary

Your Marine Collagen Powder — Action Required

Marine Collagen Powder

Identity-testing warning mapped to your ingredient profile.

Action required by Q2 2026

21 CFR 111.75(a)(1)(ii)

Ingredient Match

Matched by formula

We match FDA actions to your actual ingredients — not just product categories.

Marine Collagen Powder
Vitamin D3Marine CollagenHyaluronic Acid

Matched to FDA Warning Letter WL-2025-1847

Speed

FDA to inbox in hours

Our pipeline ingests every publication the same day.

FDA publishes

Oct 14

Pipeline ingests

Oct 14

Your inbox

<24h

Dashboard

Every product at a glance

One view. All your products. Color-coded status.

Monitored Products

Marine Collagen Powder

BHA Eye Cream SPF 15

Biotin Complex 5000mcg

Coverage

7 FDA data sources

Federal Register, guidance documents, warning letters, import alerts, Regulations.gov, openFDA, and RSS — all in one pipeline.

Federal Register

847

Warning Letters

1,247

openFDA

169K

Guidance Docs

2,761

Import Alerts

154

Regulations.gov

1,178

RSS Feeds

12

WHEN YOU NEED TO DIG DEEPER

Your dashboard is herewhen you need it.

The intelligence starts in your inbox. When you want to explore further — search enforcement history, manage products, see the full picture — your dashboard is ready.

app.policycanary.com/products

Monitored Products

Intelligence Report2h ago

Marine Collagen Powder

21 CFR 111.75(a)(1)(ii)

NovaBiotics failed identity testing for marine collagen. COA-only documentation was deemed insufficient by the FDA. Your product uses the same ingredient — this warning applies to your formulation.

Recommended Actions

  • 1Audit identity testing protocols against 21 CFR 111.75(a)(1)(ii)
  • 2Verify COA includes marine collagen-specific identity tests, not generic protein analysis
  • 3Confirm per-batch testing with your contract manufacturer

Action required by Q2 2026

Source: FDA CFSAN Warning Letters · 21 CFR 111.75(a)(1)(ii)

Interactive demo · click any product to see its intelligence

WEEKLY INTELLIGENCE

The FDA This Week

Jul 6–Jul 10, 2026

The FDA issued 14 warning letters to online vendors for the illegal sale of unapproved ketamine, esketamine, and arketamine products. Medical device manufacturers Fresenius Kabi and Windstone Medical Packaging initiated Class I corrections for infusion pump malfunctions and contaminated surgical convenience kits. Food importers faced enforcement for Foreign Supplier Verification Program violations, specifically regarding soybean meal imports by Bushman Organic Farms.

0items tracked
0sectors active
0substances flagged
0deadlines identified
Pharma19Devices8Biologics3Food2Veterinary1
Vusolimogene Oderparepvec

Cellular, Tissue, and Gene Therapies Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Biologics License Application (BLA) 125827, From Replimune, Inc. for Vusolimogene Oderparepvec

The FDA is announcing a meeting of the Cellular, Tissue, and Gene Therapies Advisory Committee to discuss Biologics License Application (BLA) 125827, submitted by Replimune, Inc. for Vusolimogene Oderparepvec. The FDA is also establishing a public docket to receive comments regarding this application.

Cell Gene Therapy
Warning Letter
ketamineesketamine

Ketamine Store / www.ketaminestore.org — Unapproved New Drugs/Misbranded

Ketamine Store / www.ketaminestore.org

The FDA issued a Warning Letter to Ketamine Store for illegally selling unapproved and misbranded ketamine and esketamine products, including liquids, troches, and nasal sprays, directly to U.S. consumers without requiring a prescription. These products lack FDA approval, fail to meet compounding exemptions under sections 503A and 503B of the FD&C Act, and bypass strict REMS requirements designed to mitigate serious safety risks. The FDA requested the immediate cessation of these sales.

Compounded Drugs
Source
Warning Letter
soybean meal

Bushman Organic Farms, Inc. — Foreign Supplier Verification Program (FSVP)

Bushman Organic Farms, Inc.

The FDA issued a Warning Letter to Bushman Organic Farms, Inc. for significant violations of the Foreign Supplier Verification Program (FSVP) regulation. The company failed to develop, maintain, and follow an FSVP for imported foods, specifically organic soybean meal imported from multiple foreign suppliers.

Plant Protein Products
Source
Safety Alert

Infusion Pump Correction: Fresenius Kabi Issues Correction for dropped or jarred Ivenix Large Volume Infusion Pumps

Fresenius Kabi has issued a Class I correction for its Ivenix Large Volume Infusion Pumps due to a risk of touchscreen malfunction (random touches or lack of responsiveness) after the device is dropped or jarred. This mechanical issue, caused by a loosened touchscreen input cable, can lead to therapy interruption or delay. The FDA classifies this as a high-risk recall with potential for serious injury or death.

Class Ii Devices
Source

Don't miss the next briefing.

The weekly FDA digest for product teams. Free. No account required.

No spam. Unsubscribe anytime.

WHO IT'S FOR

You don't have a regulatory team.
You have Policy Canary.

Whether you're the founder, the quality lead, or the person who gets the call when something goes wrong — you need product-level answers, not regulatory summaries.

Founder / CEO

32 SKUs · 40+ active ingredients

Which of my 32 SKUs is affected? I can’t cross-reference 40+ ingredients manually after every FDA notice.

QA Manager

Moisturizer line · Next audit: Q2 2026

Does the new BHA guidance apply to our moisturizer line? I need to know before our next audit.

Product Manager

Q3 launch timeline · Collagen SKU at risk

What does this collagen identity testing warning mean for our Q3 launch timeline?

VP Regulatory

47 products · 3 categories

I have 47 products. Show me which ones are affected — not a 500-page Federal Register summary.

Don't find out from a recall notice.

Your Marine Collagen Powder. Your BHA Eye Cream. Monitored by name, matched by ingredient, matched against every FDA change.

Your products monitored by name and ingredient

Action items with deadlines, not summaries

Every claim linked to the source document

All-clear confirmation when nothing affects you

The FDA cut 3,859 employees. Enforcement is less predictable, not more.

7

FDA data sources

<24 hrs

pub to email

169K

substances indexed

How many products?

5

Monthly Cost

$99

Included Products

5

Base Plan

Total: $99/mo

Includes 5 products

Full access included. No data caps. Cancel anytime.